CLNN · Clene Inc.
$4.23
-0.24 (-5.37%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$54.35M
Shares
12.85M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $933,394 |
| Mark Mortenson | Chief Science Officer | $809,426 |
| Morgan R. Brown | Chief Financial Officer | $487,650 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $1,367,727 |
| Mark Mortenson | Chief Science Officer | $1,078,619 |
| Morgan R. Brown | Chief Financial Officer | $760,567 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $1,706,605 |
| Mark Mortenson | Chief Science Officer | $1,377,982 |
| Morgan R. Brown | Chief Financial Officer | $993,698 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $2,181,629 |
| Mark Mortenson | Chief Science Officer | $1,285,504 |
| Morgan R. Brown | Chief Financial Officer | $1,158,780 |
| Dr. Robert Glanzman | Chief Medical Officer | $735,510 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $5,101,808 |
| Mark Mortenson | Chief Science Officer | $2,641,804 |
| Dr. Robert Glanzman | Chief Medical Officer | $1,546,858 |
| Robert Glanzman | Chief Medical Officer | $1,546,857 |
| Morgan R. Brown | Chief Financial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | Chief Executive Officer | $497,631 |
| Mark Mortenson | Chief Science Officer | $466,131 |
| Robert Glanzman | Chief Medical Officer | $447,203 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | — | $504,020 |
| Mark Mortenson | — | $442,520 |
| Robert Glanzman | — | $370,677 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | — | $464,504 |
| Mark Mortenson | — | $415,254 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Alison H. Mosca | Class III director | Appointed | 2026-05-22 |
| Shalom Jacobovitz | Class III director | Appointed | 2026-05-22 |
| Robert Etherington | Class III director | Appointed | 2026-05-22 |
| Matthew Kiernan AM, Ph.D., DSc | Class II director | Appointed | 2025-05-23 |
| Arjun "JJ" Desai, M.D. | Class II director | Appointed | 2025-05-23 |
| David J. Matlin | Class II director | Appointed | 2025-05-23 |
| Reed N. Wilcox | Class I director | Appointed | 2024-05-30 |
| Vallerie V. McLaughlin, M.D. | Class I director | Appointed | 2024-05-30 |
| Jonathon T. Gay | Class I director | Appointed | 2024-05-30 |
| Arjun (JJ) Desai | Class II Director | Appointed | 2023-09-19 |
| John H. Stevens | Class II director | Retired | 2023-09-19 |
| Matthew Kiernan | Class II Director | Appointed | 2023-09-19 |
| Alison H. Mosca | Class III director | Appointed | 2023-05-11 |
| Shalom Jacobovitz | Class III director | Appointed | 2023-05-11 |
| Robert Etherington | Class III director | Appointed | 2023-05-11 |
| Benjamin Greenberg, M.D., M.H.S. | Head of Medical | Appointed | 2023-03-17 |
| Robert Glanzman, M.D., FAAN | Chief Medical Officer | Retired | 2023-03-17 |
| Chidozie Ugwumba | Class II director | Resigned | 2023-02-17 |
| Tae Heum (Ted) Jeong | Chief Financial Officer | Resigned | 2022-02-02 |
| Morgan Brown | Chief Financial Officer | Appointed | 2022-02-02 |
| Vallerie V. McLaughlin, M.D. | Class III Director | Appointed | 2021-08-09 |
| Fiona Costello, M.D. | director | Resigned | 2021-06-04 |
Key facts
CIK
1822791
CUSIP
185634201
13F (30d)
31 filings
30 filers
Visit website
Investor relations